197 related articles for article (PubMed ID: 28210550)
1. Evaluating the performance of National Comprehensive Cancer Network (NCCN) breast and ovarian genetic/familial high risk assessment referral criteria for breast cancer women in an Asian surgical breast clinic.
Lim GH; Borje E; Allen JC
Gland Surg; 2017 Feb; 6(1):35-42. PubMed ID: 28210550
[TBL] [Abstract][Full Text] [Related]
2. 10-year performance of four models of breast cancer risk: a validation study.
Terry MB; Liao Y; Whittemore AS; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Chung WK; Knight JA; Southey MC; Milne RL; Goldgar D; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; John EM; Phillips KA; Daly MB; Buys SS; Hopper JL; MacInnis RJ
Lancet Oncol; 2019 Apr; 20(4):504-517. PubMed ID: 30799262
[TBL] [Abstract][Full Text] [Related]
3. Validating the IBIS and BOADICEA Models for Predicting Breast Cancer Risk in the Iranian Population.
Ghoncheh M; Ziaee F; Karami M; Poorolajal J
Clin Breast Cancer; 2017 Jun; 17(3):e113-e118. PubMed ID: 28216418
[TBL] [Abstract][Full Text] [Related]
4. Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk.
Quante AS; Whittemore AS; Shriver T; Hopper JL; Strauch K; Terry MB
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25956172
[TBL] [Abstract][Full Text] [Related]
5. Machine learning techniques for personalized breast cancer risk prediction: comparison with the BCRAT and BOADICEA models.
Ming C; Viassolo V; Probst-Hensch N; Chappuis PO; Dinov ID; Katapodi MC
Breast Cancer Res; 2019 Jun; 21(1):75. PubMed ID: 31221197
[TBL] [Abstract][Full Text] [Related]
6. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
7. Assessing BRCA carrier probabilities in extended families.
Barcenas CH; Hosain GM; Arun B; Zong J; Zhou X; Chen J; Cortada JM; Mills GB; Tomlinson GE; Miller AR; Strong LC; Amos CI
J Clin Oncol; 2006 Jan; 24(3):354-60. PubMed ID: 16421416
[TBL] [Abstract][Full Text] [Related]
8. Predictability of BRCA1/2 mutation status in patients with ovarian cancer: How to select women for genetic testing in middle-income countries.
Teixeira N; Maistro S; Del Pilar Estevez Diz M; Mourits MJ; Oosterwijk JC; Folgueira MAK; de Bock GH
Maturitas; 2017 Nov; 105():113-118. PubMed ID: 28619461
[TBL] [Abstract][Full Text] [Related]
9. Novel Interactive Tool for Breast and Ovarian Cancer Risk Assessment (Bright Pink Assess Your Risk): Development and Usability Study.
Hibler EA; Fought AJ; Kershaw KN; Molsberry R; Nowakowski V; Lindner D
J Med Internet Res; 2022 Feb; 24(2):e29124. PubMed ID: 35200148
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer in high-risk Afrikaner families: Is BRCA founder mutation testing sufficient?
Seymour HJ; Wainstein T; Macaulay S; Haw T; Krause A
S Afr Med J; 2016 Feb; 106(3):264-7. PubMed ID: 26915939
[TBL] [Abstract][Full Text] [Related]
11. Alcohol consumption, cigarette smoking, and familial breast cancer risk: findings from the Prospective Family Study Cohort (ProF-SC).
Zeinomar N; Knight JA; Genkinger JM; Phillips KA; Daly MB; Milne RL; Dite GS; Kehm RD; Liao Y; Southey MC; Chung WK; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; ; Andrulis IL; Buys SS; John EM; MacInnis RJ; Hopper JL; Terry MB
Breast Cancer Res; 2019 Nov; 21(1):128. PubMed ID: 31779655
[TBL] [Abstract][Full Text] [Related]
12. Electronic health records contain dispersed risk factor information that could be used to prevent breast and ovarian cancer.
Payne TH; Zhao LP; Le C; Wilcox P; Yi T; Hinshaw J; Hussey D; Kostrinsky-Thomas A; Hale M; Brimm J; Hisama FM
J Am Med Inform Assoc; 2020 Jul; 27(9):1443-1449. PubMed ID: 32940694
[TBL] [Abstract][Full Text] [Related]
13. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
Piver MS
Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
[TBL] [Abstract][Full Text] [Related]
14. Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model.
Terkelsen T; Christensen LL; Fenton DC; Jensen UB; Sunde L; Thomassen M; Skytte AB
Fam Cancer; 2019 Oct; 18(4):381-388. PubMed ID: 31435815
[TBL] [Abstract][Full Text] [Related]
15. Performance of BRCA1/2 mutation prediction models in male breast cancer patients.
Moghadasi S; Grundeken V; Janssen LAM; Dijkstra NH; Rodríguez-Girondo M; van Zelst-Stams WAG; Oosterwijk JC; Ausems MGEM; Oldenburg RA; Adank MA; Blom EW; Ruijs MWG; van Os TAM; van Deurzen CHM; Martens JWM; Schroder CP; Wijnen JT; Vreeswijk MPG; van Asperen CJ
Clin Genet; 2018 Jan; 93(1):52-59. PubMed ID: 28589637
[TBL] [Abstract][Full Text] [Related]
16. Value of a genetics clinic evaluation in identifying women at risk for hereditary breast-ovarian cancer syndrome.
Hinshaw JC; Zhao LP; Brimm JE; Payne TH; Hisama FM
J Genet Couns; 2021 Dec; 30(6):1591-1597. PubMed ID: 33881185
[TBL] [Abstract][Full Text] [Related]
17. Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort.
Lakeman IMM; Rodríguez-Girondo M; Lee A; Ruiter R; Stricker BH; Wijnant SRA; Kavousi M; Antoniou AC; Schmidt MK; Uitterlinden AG; van Rooij J; Devilee P
Genet Med; 2020 Nov; 22(11):1803-1811. PubMed ID: 32624571
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of National Comprehensive Cancer Network guideline-based Tool for Risk Assessment for breast and ovarian Cancer (N-TRAC): A patient-reported survey for genetic high-risk assessment for breast and ovarian cancers in women.
Ozanne EM; Howe R; Mallinson D; Esserman L; Van't Veer LJ; Kaplan CP
J Genet Couns; 2019 Jun; 28(3):507-515. PubMed ID: 30663827
[TBL] [Abstract][Full Text] [Related]
19. NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2017.
Daly MB; Pilarski R; Berry M; Buys SS; Farmer M; Friedman S; Garber JE; Kauff ND; Khan S; Klein C; Kohlmann W; Kurian A; Litton JK; Madlensky L; Merajver SD; Offit K; Pal T; Reiser G; Shannon KM; Swisher E; Vinayak S; Voian NC; Weitzel JN; Wick MJ; Wiesner GL; Dwyer M; Darlow S
J Natl Compr Canc Netw; 2017 Jan; 15(1):9-20. PubMed ID: 28040716
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
